Friday, July 4, 2025 7/4/2025

Endobronchial Supervalve for the Treatment of Emphysema

Award Number: R44HL149550
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2020
PERIOD OF PERFORMANCE END DATE: 11/30/2024

Group Awards By:

View Award Description

Endobronchial Supervalve for the Treatment of Emphysema - PROJECT SUMMARY In the United States, COPD ranks third in causes of mortality with 100,000 deaths annually. An estimated 15 million people had health care provider diagnosed COPD in 2010, and an estimated 12 million potential cases remain undiagnosed. Emphysema is a progressive, incurable form of COPD that causes significant morbidity and mortality. Emphysema is characterized by the loss of lung elasticity, reduced expiratory flow and hyperinflation. Lung volume reduction surgery is known to be an effective option for patients with moderate- severe emphysema, but few patients qualify due to the invasiveness of the procedure. Minimally invasive endobronchial lung volume reduction using one-way valves has recently been developed to address this unmet need and was approved by the FDA as recently as 2018. This proposal will validate a new, next generation Super Valve for endobronchial lung volume reduction that will broaden the use of this approach to treat patients with emphysema. Our innovation exploits the anatomy of the lobar segments of the lungs to achieve lung volume reduction using a single site instead of 3-6 sites required by the current methods. This, in turn, will lead to a faster and more efficient procedure, reducing overall surgical time and costs. This project will be completed in several sequential stages. For Phase I we will finalize concept selection for the valve design and demonstrate proof of technical concept on the bench and in acute preclinical studies that our Super Valve can be deployed in lobar airways and that it can withstand physiological stresses. In Phase II of this proposal we mature the Valve design for chronic implantation by developing features that ensure an air-tight seal and prevent migration in the setting of normal respiration and cough. We will then verify and validate a human grade valve system to FDA standards and ensure it is safe for implantation over the lifetime of the patient. The safety and durability of our valves will be demonstrated in chronic preclinical studies. The results obtained in Phase II will be used to support pre-IDE meeting with the FDA.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$5,286 )
2025	2022	CORIDEA LLC	175 CEDAR LN	TEANECK	NJ	07666	BERGEN	USA	Lung Diseases Research	000	3	4/24/2025	NON-COMPETING CONTINUATION	-$5,286
														Subtotal = -$5,286

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	CORIDEA LLC	154 W 14TH ST	NEW YORK	NY	10011	NEW YORK	USA	Lung Diseases Research	000	3	3/8/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $988,194 )
2022	2022	CORIDEA, LLC	336 W 37TH ST RM 720	NEW YORK	NY	10018	NEW YORK	USA	Lung Diseases Research	000	3	12/10/2021	NON-COMPETING CONTINUATION	$988,194
														Subtotal = $988,194

Issue Date FY: 2021 ( Subtotal = $931,412 )
2021	2021	CORIDEA, LLC	336 W 37TH ST RM 720	NEW YORK	NY	10018	NEW YORK	USA	Lung Diseases Research	000	2	11/24/2020	EXTENSION WITH OR WITHOUT FUNDS	$805,212
2021	2021	CORIDEA, LLC	336 W 37TH ST RM 720	NEW YORK	NY	10018	NEW YORK	USA	Lung Diseases Research	001	2	2/1/2021	SUPPLEMENT FOR EXPANSION	$126,200
2021	2020	CORIDEA, LLC	336 W 37TH ST RM 720	NEW YORK	NY	10018	NEW YORK	USA	Lung Diseases Research	002	1	6/28/2021	NEW	$0
														Subtotal = $931,412

Issue Date FY: 2020 ( Subtotal = $246,415 )
2020	2020	CORIDEA, LLC	336 W 37TH ST RM 720	NEW YORK	NY	10018	NEW YORK	USA	Lung Diseases Research	000	1	4/10/2020	NEW	$246,415
2020	2020	CORIDEA, LLC	336 W 37TH ST RM 720	NEW YORK	NY	10018	NEW YORK	USA	Lung Diseases Research	001	1	8/6/2020	NEW	$0
														Subtotal = $246,415

Grand Total All Awards = $2,160,735

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Endobronchial Supervalve for the Treatment of Emphysema

Award Number: R44HL149550

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2020

PERIOD OF PERFORMANCE END DATE: 11/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer